Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Immunome Inc.

Get SEC filing alerts via email and in your feed for Immunome Inc.

IMNM

Immunome Inc.

About Immunome Inc.

Immunome, Inc. is a biopharmaceutical company focused on developing targeted cancer therapies, including antibody-drug conjugates (ADCs), radioligand therapies, and small molecules. Its pipeline features clinical and preclinical assets targeting solid tumors, hematologic malignancies, and novel cancer markers like ROR1 and FAP. The company leverages proprietary payloads, innovative targets, and strategic collaborations to address unmet medical needs in oncology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Immunome Inc.

1
1
Immunome Inc. Immunome Reports $53.8 Million Net Loss in Q1 2026, Cash Reserves Decline

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Immunome Inc. Immunome Reports $212.4 Million Net Loss for 2025, Plans NDA Submission for Varegacestat

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Immunome Inc. Immunome Reports $57.5 Million Net Loss in Q3 2025, Cash Reserves Increase to $272.6 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Immunome Inc. Immunome Reports Q2 2025 Financial Results with Increased Collaboration Revenue but Higher Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Immunome Inc. Immunome Reports Q1 2025 Financial Results with Increased Collaboration Revenue and Reduced Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Immunome Inc. Immunome Inc. Reports $293M Net Loss for Fiscal Year 2024 Amid Increased R&D Costs

Via official filing (AI summary) | about 1 year ago | 0 comments